María Hernández‐Sánchez

1.4k total citations
42 papers, 451 citations indexed

About

María Hernández‐Sánchez is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, María Hernández‐Sánchez has authored 42 papers receiving a total of 451 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Genetics, 19 papers in Pathology and Forensic Medicine and 19 papers in Immunology. Recurrent topics in María Hernández‐Sánchez's work include Chronic Lymphocytic Leukemia Research (30 papers), Lymphoma Diagnosis and Treatment (19 papers) and Immunodeficiency and Autoimmune Disorders (15 papers). María Hernández‐Sánchez is often cited by papers focused on Chronic Lymphocytic Leukemia Research (30 papers), Lymphoma Diagnosis and Treatment (19 papers) and Immunodeficiency and Autoimmune Disorders (15 papers). María Hernández‐Sánchez collaborates with scholars based in Spain, United States and Austria. María Hernández‐Sánchez's co-authors include Jesús María Hernández‐Rivas, Rocío Benito, José‐Ángel Hernández‐Rivas, Miguel Quijada‐Álamo, Ana E. Rodríguez‐Vicente, Isabel González-Gascón-y-Marín, Alfonso García de Coca, Juan Luis Garcı́a, José Luis Ordóñez and Ignacio García‐Tuñón and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and PLoS ONE.

In The Last Decade

María Hernández‐Sánchez

40 papers receiving 446 citations

Peers

Countries citing papers authored by María Hernández‐Sánchez

Since Specialization

Citations

This map shows the geographic impact of María Hernández‐Sánchez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by María Hernández‐Sánchez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites María Hernández‐Sánchez more than expected).

Fields of papers citing papers by María Hernández‐Sánchez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by María Hernández‐Sánchez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by María Hernández‐Sánchez. The network helps show where María Hernández‐Sánchez may publish in the future.

Co-authorship network of co-authors of María Hernández‐Sánchez

This figure shows the co-authorship network connecting the top 25 collaborators of María Hernández‐Sánchez. A scholar is included among the top collaborators of María Hernández‐Sánchez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with María Hernández‐Sánchez. María Hernández‐Sánchez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	MARRTA: Risk matrix in advanced radiotherapy 2024 ·Physica Medica ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Enrique Hernández, C. Ferrer Albiach, J. Pardo, (unknown), (unknown), María Hernández‐Sánchez	0
2	Characterization of Human B Cell Hematological Malignancies Using Protein-Based Approaches 2024 ·International Journal of Molecular Sciences ·Cristina Jiménez, (unknown), (unknown), María Hernández‐Sánchez, Paula Díez	7
3	Generation of mouse models carrying B cell restricted single or multiplexed loss-of-function mutations through CRISPR-Cas9 gene editing 2023 ·STAR Protocols ·Elisa ten Hacken, Michaela Gruber, María Hernández‐Sánchez, (unknown), Kaitlyn Baranowski, Robert Redd, Kendell Clement, Kenneth J. Livak, Catherine J. Wu	2
4	A t(4;13)(q21;q14) translocation in B-cell chronic lymphocytic leukemia causing concomitant homozygous DLEU2/miR15a/miR16-1 and heterozygous ARHGAP24 deletions 2023 ·Cancer Genetics ·Doron Tolomeo, Antonio Agostini, Antonio Giovanni Solimando, Crocifissa Lo Cunsolo, (unknown), Orazio Palumbo, Pietro Palumbo, Massimo Carella, María Hernández‐Sánchez, Jesús María Hernández‐Rivas, Clelia Tiziana Storlazzi	1
5	Loss-of-function lesions impact B-cell development and fitness but are insufficient to drive CLL in mouse models 2022 ·Blood Advances ·Elisa ten Hacken, Shanye Yin, Robert Redd, María Hernández‐Sánchez, Kendell Clement, (unknown), (unknown), Elizabeth Witten, Shuqiang Li, Donna Neuberg, Luca Pinello, Kenneth J. Livak, Catherine J. Wu	5
6	The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment 2021 ·Diagnostics ·(unknown), Isabel González-Gascón-y-Marín, Ana E. Rodríguez‐Vicente, Miguel Quijada‐Álamo, José‐Ángel Hernández‐Rivas, María Hernández‐Sánchez, Jesús María Hernández‐Rivas	19
7	Dissecting the role of TP53 alterations in del(11q) chronic lymphocytic leukemia 2021 ·SHILAP Revista de lepidopterología ·Miguel Quijada‐Álamo, (unknown), María Hernández‐Sánchez, (unknown), Ana B. Herrero, (unknown), (unknown), (unknown), Mónica Del Rey, Teresa González, (unknown), Alfonso García de Coca, Julio Dávila, José‐Ángel Hernández‐Rivas, Helen Parker, Jonathan C. Strefford, Rocío Benito, José Luis Ordóñez, Jesús María Hernández‐Rivas	11
8	Genetic and environmental factors related to the development of myopic maculopathy in Spanish patients 2020 ·PLoS ONE ·(unknown), Sergio Recalde, Jaione Bezunartea, María Hernández‐Sánchez, (unknown), (unknown), José M. Ruiz‐Moreno, (unknown), Luís Arias, Jorge Ruiz‐Medrano, Ignacio Flores‐Moreno, (unknown), (unknown), (unknown), (unknown), Ester Carreño, Patricia Fernández‐Robredo, Alfredo García‐Layana	7
9	Prognosis Assessment of Early-Stage Chronic Lymphocytic Leukemia: Are We Ready to Predict Clinical Evolution Without a Crystal Ball? 2020 ·Clinical Lymphoma Myeloma & Leukemia ·Isabel González-Gascón-y-Marín, (unknown), Íñigo Rúa‐Figueroa, María Hernández‐Sánchez, (unknown), Miguel Quijada‐Álamo, (unknown), Carol Moreno, Rosa Collado, Blanca Espinet, Anna Puiggros, Natalia de las Heras, Francesc Bosch, José‐Ángel Hernández‐Rivas	8
10	CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition 2020 ·Leukemia ·Miguel Quijada‐Álamo, María Hernández‐Sánchez, (unknown), Ana E. Rodríguez‐Vicente, Ignacio García‐Tuñón, (unknown), Jesús María Hernández-Sánchez, Ana B. Herrero, José María Bastida, Laura San‐Segundo, Michaela Gruber, Juan Luis Garcı́a, Shanye Yin, Elisa ten Hacken, Rocío Benito, José Luis Ordóñez, Catherine J. Wu, Jesús María Hernández‐Rivas	25
11	Multiplexed CRISPR In Vivo Editing of CLL Loss-of-Function Lesions Models Transformation of Chronic Lymphocytic Leukemia into Richter's Syndrome 2020 ·Blood ·Elisa ten Hacken, Tomasz Sewastianik, Robert Redd, Geoffrey Fell, Mohamed Uduman, Michaela Gruber, Shanye Yin, Kendell Clement, Erin M. Parry, Shuqiang Li, María Hernández‐Sánchez, (unknown), Elizabeth Witten, Kaitlyn Baranowski, Lili Wang, Luca Pinello, Kenneth J. Livak, Donna Neuberg, Ruben D. Carrasco, Catherine J. Wu	1
12	The International Prognostic Index for Patients with Chronic Lymphocytic Leukemia Has the Higher Value in Predicting Overall Outcome Compared with the Barcelona-Brno Biomarkers Only Prognostic Model and the MD Anderson Cancer Center Prognostic Index 2018 ·BioMed Research International ·(unknown), (unknown), Isabel González-Gascón-y-Marín, María Hernández‐Sánchez, (unknown), (unknown), (unknown), María Ángeles Foncillas, (unknown), Jesús María Hernández‐Rivas, José‐Ángel Hernández‐Rivas	13
13	CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase 2018 ·Leukemia ·María Hernández‐Sánchez, Jana Kotašková, (unknown), Lenka Radová, David Tamborero, María Abáigar, Karla Plevová, Rocío Benito, Nikola Tom, Miguel Quijada‐Álamo, (unknown), (unknown), Karol Pál, Alfonso García de Coca, Michael Doubek, Núria López-Bigas, Jesús María Hernández‐Rivas, Šárka Pospı́šilová	10
14	A two-step approach for sequencing spliceosome-related genes as a complementary diagnostic assay in MDS patients with ringed sideroblasts 2017 ·Leukemia Research ·Kamila Janusz, Mónica Del Rey, María Abáigar, Rosa Collado, (unknown), María Hernández‐Sánchez, (unknown), Cristina Robledo, Rocío Benito, María Díez‐Campelo, Fernando Ramos, Alexander Kohlmann, Consuelo del Cañizo, Jesús María Hernández‐Rivas	3
15	Evaluation of 10 AMD Associated Polymorphisms as a Cause of Choroidal Neovascularization in Highly Myopic Eyes 2016 ·PLoS ONE ·(unknown), Sergio Recalde, Jaouad Anter, Jaione Bezunartea, María Hernández‐Sánchez, Laura García‐García, Elena Alonso, José M. Ruiz‐Moreno, (unknown), Patricia Fernández‐Robredo, Alfredo García‐Layana	11
16	MiRNA expression profile of chronic lymphocytic leukemia patients with 13q deletion 2016 ·Leukemia Research ·María Hernández‐Sánchez, Ana E. Rodríguez‐Vicente, José‐Ángel Hernández‐Rivas, Eva Lumbreras, María Eugenia Sarasquete, (unknown), Rocío Benito, Carlos Vicente‐Gutiérrez, Cristina Robledo, Natalia de las Heras, (unknown), Miguel Alcoceba, Alfonso García de Coca, Carlos Aguilar, Marcos González, Jesús María Hernández‐Rivas	9
17	MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL 2015 ·BMC Cancer ·Ana E. Rodríguez‐Vicente, Dalia Quwaider, Rocío Benito, Irena Misiewicz-Krzemińska, María Hernández‐Sánchez, Alfonso García de Coca, Rosa Fisac, (unknown), Carolina Zato, Juan F. De Paz, Juan Luis Garcı́a, María Eugenia Sarasquete, José‐Ángel Hernández‐Rivas, Juan M. Corchado, Marcos González, Norma C. Gutiérrez, Jesús María Hernández‐Rivas	20
18	Deregulation of Genes Related to Iron and Mitochondrial Metabolism in Refractory Anemia with Ring Sideroblasts 2015 ·PLoS ONE ·Mónica Del Rey, Rocío Benito, Celia Fontanillo, Francisco Campos‐Laborie, Kamila Janusz, Talía Velasco-Hernández, María Abáigar, María Hernández‐Sánchez, Rebeca Cuello, (unknown), Dionisio Martín‐Zanca, Javier De Las Rivas, Ken Mills, Jesús María Hernández‐Rivas	20
19	The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose‐intensive chemotherapy including rituximab 2015 ·British Journal of Haematology ·Maribel Forero‐Castro, Cristina Robledo, Eva Lumbreras, Rocío Benito, Jesús María Hernández-Sánchez, María Hernández‐Sánchez, Juan Luis Garcı́a, Luís A. Corchete, Mar Tormo, Pere Barba, Javier Menárguez, Jordi Ribera, Carlos Grande, Lourdes Escoda, (unknown), (unknown), Alfonso García de Coca, Josep‐María Ribera, Jesús María Hernández‐Rivas	16
20	Molecular Characterization of Chronic Lymphocytic Leukemia Patients with a High Number of Losses in 13q14 2012 ·PLoS ONE ·(unknown), José‐Ángel Hernández‐Rivas, Rocío Benito, Norma C. Gutiérrez, Juan Luis Garcı́a, María Hernández‐Sánchez, Alberto Risueño, María Eugenia Sarasquete, Encarnación Fermiñán, Rosa Fisac, Alfonso García de Coca, Guillermo Martín–Núñez, Natalia de las Heras, (unknown), Oliver Gutiérrez, Javier De Las Rivas, Marcos González, Jesús María Hernández‐Rivas	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact